Recommended across the site

Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
A licensed generic liposomal amphotericin B (Tillomed) is available. Learn about key differences compared to AmBisome Liposomal amphotericin B (Gilead) brand.
Safety strategies can minimise the risk of harms related to oxytocin infusion overdose and delayed therapy.
Intravenous thiamine for prevention of refeeding syndrome should be reserved for those with intestinal failure where the oral or enteral route is unavailable.
Intramuscular and intravenous thiamine can be used to prevent complications of alcohol dependence such as Wernicke’s encephalopathy.
The availability of pancreatic enzyme replacement therapies (PERTs) varies currently. Use our resources and mini-tool to find matches for licensed products.
The availability of medicines used to treat Attention Deficit Hyperactivity Disorder (ADHD) varies currently. Supply content is maintained regularly by DHSC.

Recommended in PGDs

Delegation of any PGD function is not permitted. However there are specific tasks that individuals other than the professional working under a PGD can fulfil.
Understand what a Patient Group Direction (PGD) is and how it is used in clinical practice.
Understanding when PGDs are a suitable mechanism for the supply and/or administration of medicines ensures an appropriate legal framework for service provision.
Understanding when PGDs are an unsuitable mechanism for the supply and/or administration of medicines ensures an alternative legal framework is applied.
Understanding where PGDs can and cannot be used for the supply and/or administration of P and GSL medicines helps ensure correct legal mechanisms in practice.
National PGD templates are developed with experts for clinical specialties. They reduce duplication and variation, and improve consistency of care.
An overview of the Spikevax (JN.1) vaccine and signposts to other useful resources
An overview of the Comirnaty 30 (JN.1) vaccine and signposts to other useful resources
An overview of the Comirnaty 10 (JN.1) ready to use vaccine and signposts to other useful resources
An overview of the Comirnaty 3 (THREE) (JN.1) concentrate vaccine and signposts to other useful resources
An example SOP for preparing Comirnaty 30 micrograms (JN.1) vaccine
An example SOP for preparing Comirnaty 10 (JN.1) ready to use vaccine
An example SOP for preparing Comirnaty 3 (THREE) (JN.1) concentrate vaccine
An example SOP for preparing Spikevax (JN.1) vaccine
All vaccinations, including live vaccines, can be given during breastfeeding. The only exception is yellow fever vaccine which is not recommended.
Continue breastfeeding during COVID-19 infection, even if dexamethasone, Paxlovid, sotrovimab or tocilzumab are required. COVID-19 vaccines can also be given.

Events

Our forthcoming conferences and webinars covering a range of Medicines Optimisation issues with SPS and other great speakers and presenters.
Search our library of past events for recordings, presentations, and interviews with speakers, all to inform your practice.

Primary care

Our primary care resources and tools are for all those working in the area, including GPs, practice pharmacists and community pharmacy teams.

If you're a healthcare professional who needs further advice, get in touch with us. You can contact us through our single email or telephone number below. Please don't share patient identifiable data with us by email.
All our advice on using medicines safely and effectively in patients with swallowing difficulties.
All our training and guidance to help decision making about the use of medicines in breastfeeding.
All our training and guidance to help decision making about the use of medicines in pregnancy.
Medication Safety Across the System (MSATS) provides resources and networking to inspire and equip individuals in promoting the safe use of medicines.
Practical guidance on effective collaboration opportunities to promote medication safety improvements
Effective communication allows for timely responses to new and emerging medication risks and the sharing of potential safety solutions.
Healthcare professionals responsible for medication safety in their organisation must deliver an appropriate response to safety alerts
High quality reporting and management of incidents and harms ensures opportunities for learning and improving medication safety
Practical guidance to ensure opportunities to learn from local intelligence, including patient harm are translated into shared local and national learning
Healthcare professionals delivering the medication safety agenda in their organisation require an understanding of national policy, frameworks and legislation
Effective use provides assurance that an organisation is aware of the most critical medication safety related information, and acts on this to improve safety
Increased medication incident reporting provides greater opportunities for learning and improving medication safety
Practical guidance to support those undertaking medication incident investigations

Planning

Regularly updated material to support the introduction of adalimumab, eculizumab, natalizumab, ranibizumab, tocilizumab and ustekinumab biosimilars.
Our annual Prescribing Outlook outputs support planning, implementation and budget planning for medicines every year.

Tools

Summarised recommendations and guidance for medicines requiring monitoring to save you time when you're making monitoring decisions with patients
Information on drug stability to help users make an informed decision on the shelf life for products prepared within aseptic facilities.
Latest information on supply issues, actions to take, alternatives to use, and expected resolution dates. Content provided by DHSC and MVA team, NHS England.
Information on stability for tablets and capsules to help create MCAs for patients. Find entries and then build and print lists specific to your MCA.
Advice on whether refrigerated medicines can or can’t be used after exposure to out-of-range temperatures. Find entries and build and print lists.